Proteome Sciences stands to receive $2.3 million from the healthcare company. That sum includes milestone patent payments and a signing fee, together with double-digit royalties on sales.
According to Proteome Sciences, the TMT chemical mass tags increase the output of proteomics experiments by reducing sample complexity. Combined with mass spectrometry and bioinformatics, the technology allows for more accurate and sensitive quantification and identification of protein biomarkers in complex biological materials such as tissue or body fluids.
Proteome Sciences also announced today a collaboration with ReGen Therapeutics for the characterization of Colostrinin, a proline-rich polypeptide complex derived from cows which ReGen is developing as a human and veterinary nutraceutical.
Proteome Sciences will apply its proprietary ProteoSHOP proteomic technologies to the biochemical characterization and activity profiling of Colostrinin.